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Background/Aims: We aimed to investigate the relation-
ships among various mutations of the p53 gene and their 
protein products, histological characteristics, and disease 
prognosis of primary colorectal cancer in Isfahan, central 
Iran. Methods: Sixty-one patients with colorectal adenocar-
cinoma were enrolled in the study. Mutations of the p53 
gene were detected by single-stranded conformation poly-
morphism and DNA sequencing. The protein stability was 
evaluated by immunohistochemistry. Patients were followed 
up to 48 months. Results: Twenty-one point mutations in 
exons 5 and 6 were detected in the tumor specimens of 14 
patients (23%). Of those, 81% and 9.5% were missense and 
nonsense mutations, respectively. There were also two novel 
mutations in the intronic region between exons 5 and 6. In 
11 mutated specimens, protein stability and protein accumu-
lation were identified. There was a relationship between the 
type of mutation and protein accumulation in exons 5 and 6 
of the p53 gene. The presence of the mutation was associ-
ated with an advanced stage of cancer (trend, p<0.009). 
Patients with mutated p53 genes had significantly lower 
survival rates than those with wild type p53 genes (p<0.01). 
Conclusions: Mutations in exons 5 and 6 of the p53 gene 
are common genetic alterations in colorectal adenocarcino-
ma in central Iran and are associated with a poor prognosis 
of the disease. (Gut	Liver	2013;7:295-302)
Key	Words: Colorectal neoplasms; p53 gene mutation; Mis-
sense; Nonsense
INTRODUCTION
According to a recent estimate, colorectal cancer is the third 
most common cancer and the fourth most common cause of 
Correspondence to: Mohammad H. Derakhshan
Section of Gastroenterology, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 44 Church Street, Glasgow G11 6NT, UK
Tel: +44-141-211-2513, Fax: +44-141-211-2895, E-mail: mohammad.derakhshan@glasgow.ac.uk
Received on March 28, 2012. Revised on July 10, 2012. Accepted on September 15, 2012. Published online on April 9, 2013.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2013.7.3.295
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cancer deaths worldwide, with 1.2 million incident cases and 
609,000 estimated deaths.1 While incidence and mortality rates 
of colorectal cancer are decreasing in the North America and 
many other Western countries, they are increasing in develop-
ing and economically transitioning countries.2 The prevalence 
of colorectal cancer is increasing in Asia.3 Currently, it is the 
fourth most common cancer in Iran.4
As a multifactorial malignancy, development and progres-
sion of colorectal cancer has been shown to be related to both 
environmental and genetic factors including mutations in p53 
gene.5-8 The p53 gene, as the most important tumor suppressor 
gene, is located on the short arm of chromosome 17 p13 which 
encodes a 35 KD nuclear phosphoprotein.9,10 The product of nor-
mal p53 gene has a role in inhibiting cell proliferation of dam-
aged cell by arresting the cell cycle or inducing them to apop-
tosis.11,12 Mutations in the p53 gene prevented cell death in the 
DNA damaged cells which would be a reason for the resistance 
to chemotherapy.13,14 The p53 gene also acts as a transcription 
factor to regulate expression of more than 100 different genes.15
The estimated frequency of p53 mutations in colorectal ad-
enocarcinoma ranges from 25% to 100% in different study 
populations.16-20 The wide variation of p53 prevalence can be 
explained by variations in study population, gender, and de-
tection techniques. The type and location of point mutation is 
another source of variation. In colorectal cancer, exons 5 and 
6 are of special interest of scientists because more than 90% of 
point mutations of p53 gene occur in theses exons.21 Individual 
frequency of p53 mutations in exons 5 and 6 is not clear. While 
observations in most of the previous studies have suggested rel-
atively high rates of mutation,22,23 Pan et al.24 reported only one 
mutation in exons 5 and 6. To date, the lowest and the highest 
rate of these mutations in patients with colorectal cancer have 
been reported from Taiwan with 31% and United Kingdom with 
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70% respectively.25 Therefore, this issue is controversial and 
merits to be investigated.
It is thought that determination of different types of muta-
tions is an important factor for therapeutic propose, i.e., plan-
ning chemotherapy or radiotherapy,26,27 particularly when it is 
known that some mutations may not induce protein production. 
The present study was designed to detect and characterize dif-
ferent mutations in exons 5 and 6 of p53 gene in a population 
of colorectal cancer patients in Isfahan, central Iran. We also 
tried to assess the relationship between different types of muta-
tions and protein stability in patients with colorectal cancer.
MATERIALS AND METHODS
1. Patients
The present study was conducted on 61 patients with primary 
intramucosal and invasive colorectal adenocarcinoma. Forty-
six (75.4%) samples were from male and 15 (24.6%) were from 
female patients. These specimens were collected from patients 
admitted to surgical departments of selected hospitals, mainly 
Al-Zahra hospital, Isfahan, Iran, between April 2006 and Octo-
ber 2009. A written informed consent was obtained from each 
patient and tissue samples have been used in the study anony-
mously. The study protocol was reviewed and approved by eth-
ics committee of Isfahan University of Medical Sciences.
2. Preparations of samples
Sampling was done before receiving radiotherapy and/or che-
motherapy. Samples were fixed in formalin 10% immediately 
after surgical resection, and formalin solution was changed 3 
hours later. Tissue passage was done after 24 hours by the tis-
sue processing instrument (Leica, Wetzlar, Germany). Series of 
4 mm thick sections from all paraffin blocks were prepared by a 
rotating microtome. Standard hematoxylin and eosin staining 
process were applied to all slides. Normal tissue biopsies from 
nontumoral area of colon were taken from the same patients as 
control. The modified Dukes’ system was used for staging can-
cer in all patients as described by Zhang et al.28
3.	Immunohistochemistry	(IHC)
IHC was carried out as described previously by Leahy et al.29 
Briefly, after cutting 4 mm thick sections, all were deparaffinised 
at 66oC and rehydrated through graded ethanol to water dilu-
tions. For antigen retrieval, sections were placed in buffer citrate 
solutions (pH 6, 0.01 M) and were then kept at 95oC for 20 min-
utes. The peroxidase activity of sections was inhibited by 3% 
H2O2 for 5 minutes and washed by phosphate buffer saline for 
three times. The mouse anti-p53 monoclonal antibody (DAKO, 
Heverlee, Belgium) was added for 1 hour at 1/50 ratio dilution 
and washed three times and incubated with biotinylated sec-
ondary antibody (DAKO) for 15 minutes at room temperature 
and washed three times. Streptavidin peroxidise was then added 
at 20 mL to each slide. The sections were then stained with 3, 
3’-diamino benzidine as substrate which produces brown non-
soluble precipitation to visualise p53 protein containing cells. 
Haematoxylin was used to stain the backgrounds. The dehydrat-
ed slides then mounted. All slides were blindly reviewed using 
light microscopy in 10 randomly selected optic fields. The motic 
light microscope and advanced motic Plus2 software (Ted Pella 
Inc., Redding, CA, USA) with ×400 were used to count cells. 
Based on percentage of cells, the slides were scored as negative, 
weak, average, and strong. The sections with nuclear staining 
in less than 10% of tumor cells were considered negative (-), 
10% to 30% were considered one positive (+), 31% to 50% were 
considered two positive (++), and staining of over 50% as three 
positive (+++) (Fig. 1).23
4.	DNA	extraction
DNA of each sample was extracted from 10 mm thick sec-
tions of paraffin-embedded tumor tissues. Three slices from 
each block were placed in 2 mL sterile Eppendorff tubes. The 
microtome blade carefully cleaned with xylene after preparation 
of each block. DNA was extracted by the phenol chloroform 
isoamil alcohol.30 The same procedure was done for control 
samples as well. 
5. The p53 gene amplification 
Exons 5 to 6 in the p53 gene were amplified by polymerase 
chain reaction (PCR) using following primers. 5´TGTTCACTT-
GTGCCCTGACT 3´, 5´GGAGGGCCACTGACAACCA 3´, and the 
length of exons 5 and 6 designed to have 489 bp.
The thermocycler for amplifying exons was set at 94oC for 
5 minutes for primary denaturation. A total of 35 cycles were 
performed including following steps: 1) denaturation at 94oC for 
0.5 minutes, 2) annealing at 56oC for 1 minute, 3) extension at 
72oC for 1 minute, and 4) final extension at 7oC for 10 minutes. 
Electrophoresis was performed for all PCR products using 1.5% 
agarose gel to determine the length of the PCR product com-
pared with a 100 bp standard ladder.24
6.	Single-stranded	conformation	polymorphism	(SSCP)	
analysis
SSCP analysis was performed as described previously.31 
Briefly, 6 to 12 mL of the PCR product was added to the same 
volume of denaturing solution containing 800 mL formamide, 
100 mL 1% bromophenol blue, 100 mL 1% xylene cyanol, 3 mL 
0.5 M ethylenediaminetetraacetic acid (EDTA), and 1 mL 10 M 
NaOH per mL solution. Samples were denaturized at 95oC for 5 
minutes and immediately transferred to ice to prevent denatur-
ation of DNA. Each sample was loaded into a 10% polyacryla-
mid gel of 0.5 mm thickness. Electrophoresis was performed in 
1×tris borate EDTA at 4oC and at 21 mA over night. Each PCR 
product was run for electrophoresis at least two times to in-
crease precision and to prevent false positive results. The bands 
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were visualized after silver staining of gel.
7. Sequencing 
After detection of mutations in exon 5 and 6 of p53 gene, 
PCR products were analyzed with SSCP. All samples with ab-
normal migration band were separated and DNA was extracted 
by a standard kit (Farayand Danesh, Tehran, Iran) and amplified 
again. These amplified DNA samples were sequenced by Macro-
Gen, Seoul, Korea. 
8. Follow-up
In order to evaluate relationship between patients’ survival 
and characteristics of p53 mutations, all subjects were followed 
up to a maximum of 48 months. We contacted family of all 
patients to ask and check the current status of the relevant pa-
tients with colorectal cancer at proper intervals.
9. Statistics analyses
The Pearson’s chi-square and Fisher exact tests (if required) 
were used to explore associations between mutations and his-
tological parameters. Using Kaplan-Meier method, survival of 
patients with and without mutations and groups in higher and 
lower cancer stages was explored and differences were tested by 
Mantel-Cox log-rank test. Results were considered to be signifi-
cant when p-value was <0.05. 
RESULTS
Tumor specimens from 61 patients with colorectal cancer 
were included in the study for the final analysis of p53 muta-
tions. Tissue specimens of six patients were excluded because 
of poor DNA quality and six new cases with colorectal cancer 
were substituted. There were 46 (75.4%) males and 15 (24.6%) 
Fig. 1. Immunohistochemistry imag-
es of p53 gene products. The specific 
monoclonal antibody was used at 
1/100 dilution. p53 protein stability 
scored between 1 and 3 in mutated 
sections. (A) Section of the normal 
proximal colon (×400). (B) Section of 
the cancerous mucosa of the proxi-
mal colon (×100). (C) Section of the 
cancerous mucosa of the distal colon 
(×400). (D) Section of the cancerous 
mucosa of the distal colon (×100).
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females. The higher number of male patients in our study may 
reflects male predominance of colorectal cancer in the popula-
tion,32 although our sample was not necessarily representative 
of the general population. The age of patients ranged from 44 
to 91 years old with the median of 62 (interquartile range, 13). 
A shown in the Table 1, men and women had similar age at the 
time of cancer diagnosis (62.5 years vs 60.0 years in male vs 
female, respectively; Mann-Whitney U test, not significant). The 
tumor stages, degree of differentiation, and location of tumor 
in colon and rectum were shown in Table 1. Fourteen patients 
(23%) had mutations in exons 5 and 6 of which three cases had 
more than one mutation in their tumoral tissues. There was a 
male predominance in the rate of p53 mutations (12/46 [26%] 
vs 2/15 [13%], in males vs females, respectively), but it was not 
statistically significant (Table 1). In total 21 point mutations 
were observed in exons 5 and 6 (Table 2). Of those mutations, 
there were 17 (81%) missenses and two (9.5%) nonsense muta-
tions. There were also two mutations in intronic region between 
exons 5 and 6, of which one mutation was associated with in-
tron deletion adjacent to exon 6. This deletion caused frameshift 
mutation in exon 6 which being reported for the first time with-
out any protein production (Table 2).
We examined the histological characteristics of tumors in pa-
tients with mutated p53. Except for two patients (14%) who had 
Table 1. Comparison of the Demographic and Histological Features 
of Colorectal Cancer Patients with and without p53 Mutations
Variable Mutated p53 Wild type p53 p-value
Gender 0.483*
   Male 12 (85.7) 34 (72.3)
   Female  2 (14.3) 13 (27.7)
Stage of cancer 0.009†
   A 2 (14.3) 24 (51.1)
   B 7 (50.0) 17 (36.2)
   C 4 (28.6) 5 (10.6)
   D 1 (7.1) 1 (2.1)
Tumor differentiation 0.444‡
   Well 9 (64.3) 27 (57.4)
   Moderate 3 (21.4) 17 (36.2)
   Poor 2 (14.3) 3 (6.4)
Tumor location 0.353*
   Proximal 3 (21.4) 17 (36.2)
   Distal colon 11 (78.6) 30 (63.8)
Data are presented as number (%).
*Fisher exact test; †p for trend; ‡Pearson’s chi-square test.
Table 2. The Features of p53 Gene Mutations in Exons 5 and 6, Their Protein Products and Associations with Age, Gender, and Tumor Location
Case no. Gender Age Mutation Amino acid change Mutation category Tumor location Previous reports
1 Male 77 GAT:TAA Asp:Stop Nonsense Proximal Yes
4 Male 58 GGA:AGG Gly:Arg Missense Proximal Yes
4 Male 58 AAA:AAT Lys:Asn Missense Proximal Yes
4 Male 58 ATA:AAT Ile:Asn Missense Proximal Yes
4 Male 58 GCT:GTC Ala:Va Missense Proximal Yes
7 Male 63 TCA:TTC Ser:Phe Missense Distal Yes
9 Male 57 GCA:GGA Ala:Gly Missense Distal Yes
17 Female 62 TTT:TTA Phe:Leu Missense Proximal Yes
21 Male 55 CCC:TCC Pro:Ser Missense Distal Yes
27 Male 68 GGG:GCG Gly:Ala Missense Distal Yes
27 Male 68 CCG:CTC Pro:Leu Missense Distal Yes
36 Male 67 CAG:CAC Glu:His Missense Distal Yes
40 Male 76 ACC:ATC Thr:Ile Missense Distal Yes
50 Female 69 GAT:GTG Asp:Val Missense Distal Yes
55 Male 49 CCA:TCA Pro:Ser Missense Distal Yes
59 Male 67 CTG:CCC Leu:Pro Missense Distal Yes
59 Male 67 GTT:ATT Val:Ile Missense Distal Yes
59 Male 67 GTG:GGG Val:Gly Missense Distal Yes
54 Male 70 ATA:TAA Ile:Stop Nonsense Distal Yes
61 Male 91 AAA:delet Lys: Frameshift Distal No
61 Male 91 GGA:TGA - Intronic Distal No
Two mutations listed at the end of the table have not been reported previously.
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intramucosal tumors, most of them (86%) had invasive adeno-
carcinoma. There was no mutation detected in control normal 
tissues taken from patients.
The frequency of mutation was increased in higher stages of 
tumor and this was statistically significant throughout all stages 
of cancer (p-value for trend=0.009). There was no significant 
association between the presence of mutation and either tumor 
location or histological differentiation of tumor (Table 1). The 
correlation between individual mutations and disease stages and 
also tumor grade were described in Table 3. Due to small num-
ber of each mutation, we were unable to apply any statistical 
test to confirm or reject associations.
The location of tumor in groups with and without mutated 
p53 was assessed. While the proportion of proximal tumor in 
mutated group appears to be lower than control group (21.4% 
vs 36.2%) but the difference was not statistically significant (Ta-
ble 1). Details of point mutations by tumor location have been 
shown in Table 2.
1. IHC
Protein stability detected by IHC was found in the specimens 
of 11 (78.6%) patients with mutations. There were six (42.9%) 
samples with the highest proportion of cancerous cells which 
was indicated by maximum colour absorption. The highest 
proportion was designated as (3+) which shows that over 50% 
of cells being stained. Three (21.4%) samples were designated 
as (+2) indicating 25% to 50% stained cells and two (14.3%) 
samples were scored (+1) with 10% to 25% stained cell. Control 
samples, taken from nontumoral tissues of patient’s colon, were 
scored as negative when the proportion of stained cells was 
less than 10% (Fig. 1). Three cases (21.4%) of cancer patients 
with mutation in exons 5 and 6 had no protein stability as IHC 
showed. There was no protein stability in specimens of cancer 
patients without p53 mutations. Therefore, presence of protein 
stability (all scores except 0) was significantly associated with 
presence of p53 mutation (p<0.001, Fisher’s exact test).
2. Survival determination 
Patients’ follow-up was started 6 months after diagnosis and 
continued up to 4 years. At the end of this period, there were 
twelve deaths among all patients: seven with mutations and 
five without any mutation. The presence of p53 mutation was 
significantly associated with lower survival rate than that those 
without mutations (log rank test, p<0.001) (Fig. 2). Similarly, 
patients with advanced stages of cancer (C and D) had signifi-
cantly worse prognosis than that those in stages A and B (log 
rank test, p<0.001). To explore the effect of stage of cancer on 
survival function of p53 mutation, the analysis was reconducted 
after adjustment for cancer stage. Although subgroup with 
higher stage of cancer had shorter survival than those in lower 
stage but this finding did not change the survival difference of 
mutated p53 versus nonmutated groups (log rank test, p=0.003). 
There were no significant associations between survival of 
patients and either histological differentiation or location of tu-
mor. 
DISCUSSION
This is the first report of the identification of missense and 
Fig. 2. Kaplan-Meier plot of survival in colorectal cancer patients 
with and without p53 mutations. The test was performed to deter-
mine the time between the first diagnosis of colorectal cancer and the 
time of death (due to colorectal cancer) during follow-up.
Table 3. Association among p53 Mutations and the Stage of Disease 
and Tumor Grades in Patients with Colorectal Cancer
Mutation
Amino acid 
change
Disease 
stage
Tumor grade
GAT:TAA Asp:Stop C Well differentiated
GGA:AGG Gly:Arg B Well differentiated
AAA:AAT Lys:Asn B Well differentiated
ATA:AAT Ile:Asn B Well differentiated
GCT:GTC Ala:Va B Well differentiated
TCA:TTC Ser:Phe A Moderately differentiated
GCA:GGA Ala:Gly B Moderately differentiated
TTT:TTA Phe:Leu B Poorly differentiated
CCC:TCC Pro:Ser B Well differentiated
GGG:GCG Gly:Ala C Well differentiated
CCG:CTC Pro:Leu C Well differentiated
CAG:CAC Glu:His A Well differentiated
ACC:ATC Thr:Ile B Well differentiated
GAT:GTG Asp:Val D Well differentiated
CCA:TCA Pro:Ser B Poorly differentiated
CTG:CCC Leu:Pro C Moderately differentiated
GTT:ATT Val:Ile C Well differentiated
GTG:GGG Val:Gly C Well differentiated
ATA:TAA Ile:Stop B Well differentiated
AAA:delet Lys: C Well differentiated
GGA:TGA - C Well differentiated
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nonsense mutations in exons 5 and 6 of p53 gene in patients 
with colorectal cancer from Isfahan, Central Iran. The high fre-
quency of p53 mutations in exons 5 and 6 in this population 
is similar to those from other ethnic origins. Although most of 
the 21-point mutations in our study were reported previously 
by other authors, but this study added two novel point muta-
tions to medical literature for the first time. In addition, direct 
sequencing showed that in the three patients with primary 
colorectal cancer there were more than one mutation. We also 
showed very low rate of nonsense mutations. 
The results of our study are consistent with several published 
studies from different populations. Yamashita et al.16 showed 
p53 gene mutations in five out of 20 specimens (25%) from 
patients with sporadic colorectal cancer in Japan. Mahdavinia 
et al.22 in a study conducted on a population from Northern Iran 
showed a total of 40% mutation rate of p53 gene, exons 5, or 6. 
The abnormal migration in exons 5 and 6 in the p53 gene has 
been described by Leahy et al.29 in the 20% of 66 samples; of 
which there were seven abnormal bands in exon 5 and six were 
in exon 6. Contrary to our results, Pan et al.24 reported only one 
mutation located in exons 5 and 6 in a group of 97 patients 
with rectal carcinoma. 
Protein stability was another finding which was evident in 
79% of our mutated specimens. The presence of protein stability 
in sample cancer cells has been regarded as a sign of mutation 
and IHC can be used for detection of p53 protein.24 However, 
there were some limitations in utilization of IHC because it is 
useful only when a mutation can normally leads to protein 
stability. It means that IHC would not be useful to detect any 
nonsense silent mutation33,34 due to absence or incomplete pro-
duction of a protein. Substitution of stop codon with the normal 
codon or presence of a deletion in any exons which lead to pro-
tein production are possible explanations for this phenomenon. 
Therefore, relying only on IHC for diagnostic purposes may lead 
to an inappropriate treatment protocols in patients with colorec-
tal cancer. This phenomenon may also happen in the opposite 
direction, in which occurrence of some protein stabilities may 
not due to mutation. We recommend all these possibilities to be 
considered in cancer laboratories and to be equipped with addi-
tional accurate molecular and sequencing techniques along with 
IHC. 
Our findings showed that there was more than one mutation 
in three (5%) patients with colorectal cancer which is compara-
ble to another study from Iran with same rate22 and lower than 
the rate of 17% which has been reported by Leahy et al.29
We tried to investigate association between location of tumor 
and frequency of p53 mutations. Although there was a weak 
tendency toward higher frequency of mutations in distal tumors 
but the difference was statistically nonsignificant. A number 
of studies showed that the rate of mutations is higher in tu-
mors of distal part compared to proximal colon.8,35 This may be 
due to higher exposure of mucosa to more concentrated toxic 
substances contributing to cancer development in distal versus 
proximal colon. 
Although the study did not focus on the role of gender, re-
sults suggested that the mutation rates in female were less than 
that in males (13% vs 26% in females and males, respectively), 
but this difference did not reach statistically significant level 
due to small number of female patients. Although underlying 
mechanism of the male predominance in the rate of p53 muta-
tions is not clear, perhaps there are common explanations for 
male predominance in the carcinogenesis of colorectal cancer 
and parallel genetic alterations including p53 mutations.32 Ei-
ther excess exposure to some environmental risk factor among 
men or some protective endogen pathways among women are 
main factors to be investigated in future. Much stronger male 
predominance has been described in upper gastrointestinal tract 
adenocarcinoma and some protective endogen factors has been 
suggested previously.36
We were able to investigate the prognosis of cancer in pa-
tients with mutated versus nonmutated p53 gene. The mutated 
group had apparently shorter survival than group with wild 
type p53 gene in their tumor. While this finding is consistent 
with the results of several studies,37-39 but association between 
p53 overexpression and prognosis has not been supported by 
a number of studies.40,41 Considering the conflicting results on 
usefulness of p53 gene mutation for prediction of prognosis, 
and presence of robust clinicopathologic staging systems, i.e., 
Duke classification, a recent guideline did not support routine 
application of p53 gene mutation and some other tumor makers 
for prognostic purpose in colorectal cancer.42
In summary, although the current study suffers from relative-
ly small number of cancer patients, which is reflected by some 
weak associations, it is first attempt to describe p53 gene muta-
tion in colorectal cancer patients from Isfahan, Central Iran. Re-
sults of this study may help scientists to understand similarities 
and differences of p53 mutations among different populations 
with various life style behaviours and genetic backgrounds. It 
may also help clinicians to be conscious about magnitude of 
genetic alterations which are known to be of predictive value in 
clinical trials.
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